SCHEMBL2650329

SCHEMBL2650329

Fc1ccccc1-c1cccnc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.59
RAB9A P51151 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
CYP2A6 P11509 6/20 0.56
ALDH1A1 P00352 3/20 0.56
CYP3A4 P08684 3/20 0.56
CYP1A2 P05177 1/20 0.56
KCNA5 P22460 1/20 0.51
KDM4E B2RXH2 2/20 0.51
HPGD P15428 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
GLA P06280 1/20 0.51
GAA P10253 1/20 0.51
PIM1 P11309 1/20 0.51
CYP11B1 P15538 2/20 0.50
TDO2 P48775 2/20 0.50
KDR P35968 1/20 0.49
EPHB4 P54760 1/20 0.49
TEK Q02763 1/20 0.49
AKR1C3 P42330 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20541087 0.84 CYP2A6 (0.70) NPC1RAB9ACYP2A6ALDH1A1CYP3A4
SCHEMBL30026143 0.84 CYP2A6 (0.70) NPC1RAB9ACYP2A6ALDH1A1CYP3A4
SCHEMBL21110859 0.82 CYP2A6 (0.67) CYP2A6ALDH1A1CYP3A4CYP1A2KCNA5
SCHEMBL12853987 0.82 CYP2A6 (0.67) CYP2A6ALDH1A1CYP3A4CYP1A2KCNA5
SCHEMBL4621666 0.80 CYP2A6 (0.64) CYP2A6ALDH1A1CYP3A4CYP1A2KCNA5
SCHEMBL31017586 0.80 CYP2A6 (0.64) CYP2A6ALDH1A1CYP3A4CYP1A2KCNA5
SCHEMBL29914836 0.80 RPS6KA3 (0.54) CYP2A6ALDH1A1CYP3A4CYP1A2CYP11B1
SCHEMBL1422763 0.79 NPC1 (0.68) NPC1RAB9ATDP1ALDH1A1CYP3A4
SCHEMBL18952883 0.79 PIM1 (0.46) NPC1RAB9ATDP1CYP2A6ALDH1A1
SCHEMBL15624620 0.79 TDO2 (0.56) NPC1RAB9ATDP1CYP2A6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230371358-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2023-11-16 US disclosed
US-11179710-B2 Direct palladium-catalyzed aromatic fluorination PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2021-11-23 US disclosed
EP-3426654-B1 DIRECT PALLADIUM-CATALYZED AROMATIC FLUORINATION HARVARD COLLEGE (US) 2021-10-20 EP disclosed
WO-2021121420-A1 BENZOPYRAZOLE COMPOUND AND INTERMEDIATE, PREPARATION METHOD, AND APPLICATION THEREOF 江苏凯迪恩医药科技有限公司 2021-06-24 WO disclosed
CN-109790146-A Medical compounds 阿尔麦克探索有限公司 2019-05-21 CN disclosed
US-20190099748-A1 DIRECT PALLADIUM-CATALYZED AROMATIC FLUORINATION PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2019-04-04 US disclosed
EP-3426654-A1 DIRECT PALLADIUM-CATALYZED AROMATIC FLUORINATION President and Fellows of Harvard College (US) 2019-01-16 EP disclosed
US-10160745-B2 Piperidine and azepine derivatives as prokineticin receptor modulators TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-12-25 US disclosed
US-20180009780-A1 PIPERIDINE AND AZEPINE DERIVATIVES AS PROKINETICIN RECEPTOR MODULATORS TAKEDA PHARMACEUTICALS CO (JP) 2018-01-11 US disclosed
EP-3030553-B1 PIPERIDINE AND AZEPINE DERIVATIVES AS PROKINETICIN RECEPTOR MODULATORS TAKEDA PHARMACEUTICALS CO (JP) 2018-01-03 EP disclosed
EP-1381606-B1 IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME (GB) 2005-07-20 EP disclosed
US-6900215-B2 For therapy of disorders of central nervous system, including anxiety, convulsions and cognitive disorders MERCK SHARP & DOHME LTD. (GB) 2005-05-31 US disclosed
US-20040171633-A1 (1, 8) naphthyridines as gaba ligands, their pharmaceutical compositions and uses MERCK SHARP & DOHME LTD. (GB) 2004-09-02 US disclosed
CN-1498218-A Imidazo-pyrimidine derivatives as GABA receptor ligands Ĭ�ˡ�����-��ķ��˾ 2004-05-19 CN disclosed
EP-1381606-A1 IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LTD. (GB) 2004-01-21 EP disclosed
WO-2003006464-A1 (1,8) NAPHTHYRIDINES AS GABA LIGANDS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES MERCK SHARP & DOHME LIMITED (GB) 2003-01-23 WO disclosed
US-20020193385-A1 Imidazo-pyrimidine derivatives as ligands for gaba receptors MERCK SHARP & DOHME (UK) LIMITED (GB) 2002-12-19 US disclosed
WO-2002074773-A1 IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 2002-09-26 WO disclosed
WO-2002074772-A1 IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 2002-09-26 WO disclosed
US-4797490-A Process for the preparation of 3-(2'-fluorophenyl)pyridine PFIZER INC. (US) 1989-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193385-A1 Imidazo-pyrimidine derivatives as ligands for gaba receptors GABRA3, GABRA1, GABRA2 NPC1 2277/4885RAB9A 2499/4885TDP1 1190/4885
US-11179710-B2 Direct palladium-catalyzed aromatic fluorination KRAS, NRAS, DDT NPC1 3154/4885RAB9A 45/4885TDP1 2627/4885
US-20190099748-A1 DIRECT PALLADIUM-CATALYZED AROMATIC FLUORINATION KRAS, NRAS, DDT NPC1 3154/4885RAB9A 45/4885TDP1 2627/4885
US-10160745-B2 Piperidine and azepine derivatives as prokineticin receptor modulators GIPR, PROKR1, PROKR2 NPC1 2850/4885RAB9A 958/4885TDP1 4681/4885
US-20040171633-A1 (1, 8) naphthyridines as gaba ligands, their pharmaceutical compositions and uses GABRA1, GABRA4, GABRA6 NPC1 397/4885RAB9A 1558/4885TDP1 1555/4885
US-20180009780-A1 PIPERIDINE AND AZEPINE DERIVATIVES AS PROKINETICIN RECEPTOR MODULATORS GIPR, PROKR1, PROKR2 NPC1 2850/4885RAB9A 958/4885TDP1 4681/4885
US-20230371358-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES LIFR, SOD1, ROS1 NPC1 4515/4885RAB9A 257/4885TDP1 4776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.